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Abstract
Background: In the last decade the importance of ethnicity, socio-economic and gender differences in relation
to disease incidence, diagnosis, and prognosis has been realized. Differences in these areas have become a major
health policy focus in the United States. Our study was undertaken to examine the demographic and clinical
features of chronic myelogenous leukemia (CML) patients presenting initially at the LAC+USC Medical Center,
which serves an ethnically diverse population.
Results: Patients were evenly split by gender, overwhelmingly Hispanic (60.9%), and quite young (median age 39,
range 17–65) compared with previously reported CML patient populations. Previous CML studies identified
significant anemia (Hgb <12 g/dl), significant thrombocytosis (platelets >450 × 109/l), and significant leukocytosis
(WBC >50 × 109/l) as significant adverse pretreatment prognostic factors. Using these indicators, in addition to
the validated Hasford and Sokal scores, patients were stratified and analyzed via gender and ethnicity. A
significantly greater proportion of women presented with significant anemia (p = 0.019, Fisher's exact test) and
significant thrombocytosis (p = 0.041, Fisher's exact test) compared to men, although no differences were found
in risk stratification or treatment response. MCV values for women were significantly (p = 0.02, 2-sample t-test)
lower than those for men, suggesting iron deficiency anemia. Focusing on ethnicity, Hispanics as a whole had
significantly lower Hasford risk stratification (p = 0.046, Fisher's exact test), and significantly greater likelihood (p
= 0.016, Fisher's exact test) of achieving 3-month complete haematological remission (CHR) compared with non-
Hispanics at LAC+USC Medical Center, though differences in treatment outcome were no longer significant with
analysis limited to patients treated with first-line imatinib.
Conclusion: Female CML patients at LAC+USC Medical Center present with more significant adverse pre-
treatment prognostic factors compared to men, but achieve comparable outcomes. Hispanic patients present
with lower risk profile CML and achieve better treatment responses compared to non-Hispanic patients as a
whole; these ethnic differences are no longer significant when statistical analysis is limited to patients given
imatinib as first-line therapy. Our patients achieve response rates inferior to those of large-scale national studies.
This constellation of findings has not been reported in previous studies, and is likely reflective of a unique patient
population.
Published: 24 July 2009
Journal of Hematology & Oncology 2009, 2:30 doi:10.1186/1756-8722-2-30
Received: 2 July 2009
Accepted: 24 July 2009
This article is available from: http://www.jhoonline.org/content/2/1/30
© 2009 Lee et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Hematology & Oncology 2009, 2:30 http://www.jhoonline.org/content/2/1/30
Page 2 of 8
(page number not for citation purposes)
Background
In the last decade the importance of ethnicity, socio-eco-
nomic and gender differences in relation to disease inci-
dence, diagnosis, and prognosis has been realized.
Differences in these areas have become a major health
policy focus in the United States. Several studies have
addressed ethnic differences in the behavior and mortality
of prostate cancer and breast cancer and have been able to
demonstrate a trend toward more aggressive disease in an
African-American population when compared to a Cauca-
sian-non Hispanic population [1-6]. Studies have also
shown that uninsured and poorer patients are far more
likely to have advanced disease when diagnosed with can-
cer compared to those with private coverage [1]. Using
SEER registry data, there is a known higher incidence of
ALL among the Hispanic population, while there is a
lower incidence of acute myelogenous leukaemia (AML)
and chronic myelogenous leukaemia (CML) in the His-
panic population [7]. Additionally it has been shown that
there is a higher incidence of acute promyelocytic leukae-
mia (APL) in the Hispanic population when compared to
a non-Hispanic population [8].
CML is a clonal myeloproliferative malignancy caused by
a specific chromosomal translocation involving chromo-
somes 9 and 22, giving rise to the "Philadelphia Chromo-
some," which fuses the two genes bcr and abl [9-14]. There
are approximately 4500 patients diagnosed with CML
every year in the United States, accounting for 15% of all
new leukemias [14]. The median age of patients at presen-
tation is 45–55 years old, with a slight male predomi-
nance [14]. The disease historically was characterized by
an ordered progression from a chronic phase, to acceler-
ated phase, to finally an acute "blastic" phase followed by
death. Key breakthroughs in the treatment of this disease
came about in the late 1980's early 1990's with bone mar-
row transplants [15,16], followed by the introduction of
imatinib in the late 1990's, which has dramatically
impacted the survival of patients with this disease, now
approaching 80% at ten years [17-23]. It was recently
shown that women with CML presented with more
adverse risk factors, but had an advantage in overall sur-
vival during the interferon era [24]. Current research has
begun to explore clinic-epidemiologic information on
CML from developing countries, and a recent study has
examined a cohort of Hispanic CML patients in Mexico
City [25].
The Los Angeles County-University of Southern California
(LAC+USC) Medical Center is a large publicly-funded
urban medical center in the Los Angeles serving a diverse
ethnic population with a high proportion of Hispanic and
minority patients. In this study we evaluated the present-
ing and prognostic features of patients diagnosed at
LAC+USC Medical Center with CML, including the calcu-
lation of the validated Hasford [26] and Sokal [27] prog-
nostic scores. We evaluated the patients based on gender
and ethnicity to evaluate the role these factors imparted
upon CML presentation. We then correlated prognostic
features with treatment response data, specifically the
three-month complete haematological remission rate
(CHR), to evaluate the predictive power of our pre-treat-
ment analysis.
Results
Unique characteristics of CML patients in Los Angeles
Notable features of our overall CML patient cohort at
LAC+USC Medical Center are summarized in Table 1. The
median age of our CML patient group is 39 years old, with
a range of 17–65 years old. Patient gender distribution is
approximately equal. The patient population is over-
whelmingly Hispanic in ethnicity (60.9%), reflecting the
overall patient population served by LAC+USC Medical
Center. Of our non-Hispanic patients, the next most com-
mon ethnicity is Asian (23.0%), followed by African
American (11.5%), and lastly Caucasian (4.6%). A major-
ity of the patients for whom treatment information is
available were treated with imatinib mesylate (Gleevec) –
62.5%; virtually all patients treated with other regimens
presented to LAC+USC prior to the introduction of this
drug. The vast majority (91.9%) of patients presented in
chronic phase CML.
Significant proportions of our CML cohort present with
hematological features identified in previous studies as
significant adverse pre-treatment factors, such as a low
hemoglobin, high platelet count, and high white blood
cell count (Table 1). For those patients for whom we were
able to calculate the validated Hasford and Sokal scores,
patients trended toward the lower-risk categories by both
measures. For those patients for whom we had sufficient
treatment response data, the majority (59.6%) achieved
complete hematologic remission (CHR) at 3 months.
When analysis is limited to patients who were given imat-
inib as first-line treatment, overall 3 month CHR is 75%.
These overall results compare unfavourably with treat-
ment response rates achieved in large-scale national trials,
which have reported three-month CHR rates of up to 86%
for CML patients treated with imatinib after interferon
therapy, and overall CHR rates of 95% for the entire trial
duration [21,22].
Gender-based differences in CML presentation and 
treatment response
Notable characteristics of our CML patient population,
stratified by gender, are presented in Table 2. Differences
in age and ethnic distribution are not significant. A signif-
icantly greater proportion (p = 0.019, Fisher's exact test) of
females compared to males present with significantly low
hemoglobin (<12 g/dL). An analysis of our MCV dataJournal of Hematology & Oncology 2009, 2:30 http://www.jhoonline.org/content/2/1/30
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found that values for women were significantly (p = 0.02,
2-sample t-test) lower than those for men, suggesting the
presence of iron-deficiency anemia as a potential contrib-
uting factor. Additionally, a significantly greater propor-
tion (p = 0.041, Fisher's exact test) of females compared to
males present with significantly elevated platelet counts
(>450 × 109/L). Proportional differences for white blood
cell count data are not significant. These three characteris-
tics were identified in previous studies as significant
adverse pre-treatment prognostic factors [27-29]. Gender-
based differences between mean values for haematologi-
cal data, relative Hasford and Sokal score distributions,
and relative rates of 3-month CHR, stratified by imatinib
treatment or overall, were not significant.
Ethnicity-based differences in initial CML patient 
presentation
Notable characteristics of our CML patient population,
stratified by ethnicity, are presented in Table 3. Differ-
ences in age and gender distribution are not significant.
Ethnicity-stratified differences in mean hemoglobin, leu-
kocyte, and platelet counts were not significant. The pro-
portions of patients in different clinical categories for
these haematological measures was also insignificant.
These three characteristics were identified in previous
studies as significant negative pre-treatment prognostic
factors [27-29]. Ethnicity-stratified Hasford score distribu-
tions were significantly different (p = 0.046, Fisher's exact
test), with Hispanic patient scores distributed more heav-
ily in lower-risk categories compared to non-Hispanic
patients. Ethnicity-stratified Sokal scores nonsignificantly
trended toward the same results (p = 0.11, Fisher's exact
test), with Hispanic patient scores trending towards
lower-risk categories compared to non-Hispanic patients.
When looking at all patients, a significantly greater pro-
portion (p = 0.016, Fisher's exact test) of Hispanic patients
achieved CHR at 3 months compared to non-Hispanic
patients as a whole. When analysis is limited to patients
given imatinib as first-line treatment, these differences are
no longer significant (p = 0.23, Fisher's exact test)
Validation of Calculated Hasford and Sokal Scores
Statistical analysis was performed to validate our calcu-
lated Hasford and Sokal scores for our CML patient
cohort, as presented in Table 4. When considering all
treatments, lower risk-profile Hasford scores were signifi-
cantly (p = 0.035, Fisher's exact test) associated with
greater likelihood of achieving 3-month CHR, while lower
risk-profile Sokal scores were also significantly (p = 0.015,
Fisher's exact test) associated with a greater likelihood of
achieving 3-month CHR. When analysis is limited to
patients given imatinib as first-line treatment, these differ-
ences remain significant for both the Hasford (p = 0.045,
Fisher's exact test) and the Sokal (p = 0.0043, Fisher's
exact test) scores.
Discussion
In this current study we review several of the prognostic
presentation factors of a large population of mainly His-
panic patients diagnosed and treated at LAC+USC Medical
Center. An interesting observation from our study is the
striking average age difference in this largely Hispanic
population compared to data in the SEER registry [7],
although our cohort's median age is concordant with a
Hispanic CML cohort studied in Mexico City [25]. SEER
registry data suggests that the incidence of CML increases
Table 1: Overall CML Patient Characteristics (n = 87 patients)
Characteristic # of Patients (%)
Age in years (n = 86)
<60 79 (91.9%)
>/=60 7 (8.1%)
Gender (n = 87)
Male 44 (50.6%)
Female 43 (49.4%)
Ethnicity (n = 87)
Hispanic 53 (60.9%)
Non-Hispanic 34 (39.1%)
White 4 (4.6%)
African American 10 (11.5%)
Asian 20 (23.0%)
Imatinib Treatment (n = 64)
Yes 40 (62.5%)
No 24 (37.5%)
Hemoglobin (g/dL) (n = 83)
<12 57 (68.7%)
>/=12 26 (31.3%)
WBC count (× 109/L) (n = 85)
<50 22 (25.9%)
>/=50 63 (74.1%)
Platelets (× 109/L) (n = 82)
<450 50 (61.0%)
>/=450 32 (39.0%)
CML Phase (n = 74)
Chronic 68 (91.9%)
Accelerated 4 (5.4%)
Blastic 2 (2.7%)
Hasford Score (n = 64)
</=780 low-risk 35 (54.7%)
>780 and </=1480 intermediate 21 (32.8%)
>1480 high-risk 8 (12.5%)
Sokal Score (n = 65)
<0.8 good prognosis 25 (38.5%)
0.8–1.2 moderate prognosis 24 (36.9%)
>1.2 poor prognosis 16 (24.6%)
CHR at 3 months, all treatments (n = 47)
Yes 28 (59.6%)
No 19 (40.4%)
CHR at 3 months, imatinib only (n = 36)
Yes 27 (75%)
No 9 (25%)
Demographic and clinical features of CML patients presenting initially 
at LAC+USC Medical Center are presented.Journal of Hematology & Oncology 2009, 2:30 http://www.jhoonline.org/content/2/1/30
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with age in all ethnicities with a greater incidence in the
Caucasian-non Hispanic population [7]. Additionally,
our population's overall response to treatment, as meas-
ured by 3-month CHR rates, is inferior compared to those
found in previous large-scale trials, which have set imat-
inib as the benchmark in CML therapy [17-23].
In this study we have confirmed in our largely Hispanic
patient population that women present with higher risk
features, specifically a higher proportion of patients rela-
tive to men, in low hemoglobin and high platelet count
categories. These factors have been demonstrated in prior
studies to have an adverse effect upon outcomes [27-29].
In our largely Hispanic population of patients we have
shown that associations between female gender and low-
ered hemoglobin, as well as elevated platelet count, seen
in other large CML studies [24] hold true in our popula-
tion. In fact, we suspect that the main contributing factor
to females presenting with lower hemoglobin and higher
platelet counts is iron deficiency. In our population, iron
studies were lacking in the majority of patient records, but
when using mean corpuscular volume, a surrogate for
iron status, we see that women present with a significantly
lower MCV than compared to men. It is not clear what
role, if any, iron deficiency would play in the pathogenesis
and progression of CML. Despite the presence of these fea-
tures, however, our study was unable to demonstrate gen-
der-stratified differences in Hasford or Sokal score
distribution, or in treatment outcome as defined by 3-
month CHR. This is at odds with previous studies [24],
which found less favourable risk profiles, but longer sur-
vival times, during the interferon era. We postulate that
these differences may be attributable to the unique ethnic
and socio-economic profile of our patient population, as
well the advent of imatinib, a highly efficacious treatment
not yet developed at the time that the Hasford and Sokal
scores were validated.
We demonstrated lower risk stratification scores for His-
panic patients versus non-Hispanic patients combined.
Hispanic patients were also more likely to achieve 3
month CHR compared to non-Hispanic patients when all
patients were analysed, although these differences were
no longer significant when analysis was limited to
patients given imatinib as first-line treatment. These dif-
ferences may more likely be due to non-Hispanic ethnici-
Table 2: Patient Stratification by Gender
# of Patients (%)
Characteristic Female Male P Value
Age (yrs) (n = 86) 0.26
<60 37 (88.1%) 42 (95.5%)
>/=60 5 (11.9%) 2 (4.5%)
Ethnicity (n = 87) 0.19
Hispanic 23 (53.5%) 30 (68.2%)
Non-Hispanic 20 (46.5%) 14 (31.8%)
Hemoglobin (g/dL) (n = 83) 0.019
<12 34 (80.9%) 23 (56.1%)
>/=12 8 (19.1%) 18(43.9%)
Leukocyte count (× 109/L) (n = 85) 0.46
<50 13 (30.2%) 9 (21.4%)
>/=50 30 (69.8%) 33 (78.6%)
Platelets (× 109/L) (n = 82) 0.041
<450 20 (48.8%) 30 (73.2%)
>/=450 21 (51.2%) 11 (26.8%)
Hasford Score (n = 64) 1
</=780 low-risk 19 (52.8%) 16 (57.1%)
>780 and </=1480 intermediate 12 (33.3%) 9 (32.1%)
>1480 high-risk 5 (13.9%) 3 (10.7%)
Sokal Score (n = 65) 0.39
<0.8 good prognosis 12 (33.3%) 13 (44.8%)
0.8–1.2 moderate prognosis 16 (44.4%) 8 (27.6%)
>1.2 poor prognosis 8 (22.2%) 8 (27.6%)
CHR at 3 months, all treatments (n = 47) 0.23
Yes 13 (50%) 15 (71.4%)
No 13 (50%) 6 (28.6%)
CHR at 3 months, imatinib only (n = 36) 0.13
Yes 12 (63.2%) 15 (88.2%)
No 7 (38.4%) 2 (11.8%)
Selected demographic and clinical features of CML patients are presented, stratified by gender.Journal of Hematology & Oncology 2009, 2:30 http://www.jhoonline.org/content/2/1/30
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ties presenting and performing more poorly than the
norm, rather being attributable to superior prognostic fea-
tures and outcomes for Hispanic patients. The vast major-
ity of our non-Hispanic patients were African American or
Asian. Indeed, our results may reflect a trend of non-His-
panic minority CML patients presenting and performing
more poorly than national averages. We believe that
socio-economic factors may play a role in explaining these
differences. Additional studies are ongoing. Additionally,
the disparities between risk stratification and treatment
outcome in imatinib-treated patients may be attributed to
the advent of imatinib as first-line therapy for CML, not
yet developed at the time that the Hasford and Sokal
scores were validated. However, we cannot rule out the
possibility that perhaps a biological/genetic factor also
contributes to this observed ethnic differences in disease
presentation and behaviour, as shown previously at our
Table 3: Patient Stratification by Ethnicity
# of Patients (%)
Characteristic Hispanic NH P Value
Age (yrs) (n = 86) 1
<60 49 (92.5%) 30 (90.9%)
>/=60 4 (7.5%) 3 (9.1%)
Gender (n = 87) 0.19
Female 23 (43.4%) 20 (58.8%)
Male 30 (56.6%) 14 (41.2%)
Hemoglobin (g/dL) (n = 83) 1
<12 34 (68%) 23 (69.7%)
>/=12 16 (32%) 10 (30.3%)
Leukocyte count (× 109/L) (n = 85) 0.13
<50 10 (10.6%) 12 (35.3%)
>/=50 41 (80.4%) 22 (64.7%)
Platelets (× 109/L) (n = 82) 0.64
<450 29 (58%) 21 (65.6%)
>/=450 21 (42%) 11 (34.4%)
Hasford Score (n = 64) 0.046
</=780 low-risk 23 (56.1%) 12 (52.2%)
>780 and </=1480 intermediate 16 (39.0%) 5 (21.7%)
>1480 high-risk 2 (4.9%) 6 (26.1%)
Sokal Score (n = 65) 0.11
<0.8 good prognosis 19 (45.2%) 6 (26.1%)
0.8–1.2 moderate prognosis 16 (38.1%) 8 (34.8%)
>1.2 poor prognosis 7 (16.7%) 9 (39.1%)
CHR at 3 months, all treatments (n = 47) 0.016
Yes 20 (76.9%) 8 (38.1%)
No 6 (23.1%) 13 (61.9%)
CHR at 3 months, imatinib only (n = 36) 0.23
Yes 19 (82.6%) 8 (61.5%)
No 4 (17.4%) 5 (38.5%)
Selected demographic and clinical features of CML patients are presented, stratified by ethnicity.
Table 4: Validation of Calculated Hasford and Sokal Scores
3-mo CHR, all treatments (n = 35) 3-mo CHR, imatinib only (n = 32)
Yes No P Value Yes No P Value
Hasford Score 0.035 0.0454
</=780 low-risk 17 (85%) 3 (15%) 16 (88.9%) 2 (11.1%)
>780 and </=1480 intermediate 5 (41.7%) 7 (58.3%) 5 (45.5%) 6 (55.5%)
>1480 high-risk 2 (66.7%) 1 (33.3%) 2 (66.7%) 1 (33.3%)
Sokal Score 0.015 0.0043
<0.8 good prognosis 14 (93.3%) 1 (6.7%) 13 (100%) 0 (0%)
0.8–1.2 moderate prognosis 7 (58.3%) 5 (41.7%) 7 (58.3%) 5 (41.7%)
>1.2 poor prognosis 3 (37.5%) 5 (62.5%) 3 (42.9%) 4 (57.1%)
Achievement of 3 month CHR is presented, stratified by Hasford and Sokal risk profile categories.Journal of Hematology & Oncology 2009, 2:30 http://www.jhoonline.org/content/2/1/30
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institution for APL in the Hispanic patient populations
[8].
Our cohort as a whole, achieved 3-month CHR rates infe-
rior to those examined in previous large-scale CML trials,
which have yielded 3-month CHR rates of up to 86 per-
cent [17-23]. To our knowledge this is the first report of a
large cohort of Hispanic patients with CML diagnosed in
the United States. There has been a recent study examin-
ing a CML cohort at a single institution in Mexico City
[25]. Additionally, there are several studies addressing
Hispanic patients and transplant outcome in leukemia in
general with a small sub population of patients with CML
[30-33]. These studies, however, suggest that Hispanic
patients have a worse outcome following transplantation
and may have more barriers to this treatment option
when compared to Caucasian non-Hispanic patients. In
these studies presenting factors were not addressed. The
variation between these studies and our own findings may
be attributable to the factors discussed above, and may
simply be findings unique to our patient population.
Additional studies are ongoing.
We acknowledge that our study is limited by numerous
logistical difficulties. Complete data sets were not availa-
ble for all 87 patients identified in this study, limiting the
number of patients for whom we could provide a full
demographic profile and calculate Sokal and Hasford
scores. Spleen sizes were not available for the vast major-
ity of patients, so an average value was interpolated for the
purpose of calculating Sokal and Hasford scores. Addi-
tionally, treatment response and long-term followup data
was not available for numerous patients included in the
pre-treatment analysis, limiting our statistical power in
analysing the association between pre-treatment prognos-
tic factors and treatment response. We were, however, able
to validate our Hasford, Sokal, and treatment response
data, as lower risk profiles were appropriately significantly
associated with better treatment response, both when
looking at all patients regardless of treatment, and when
analysis was limited to patients given imatinib as first-line
treatment.
Conclusion
We conclude that female CML patients at LAC+USC Med-
ical Center present with more significant adverse pre-treat-
ment prognostic factors identified in previous studies
compared to men, while Hispanic patients present with
lower risk profile CML and achieve better treatment
responses compared to our non-Hispanic patients as a
whole; these ethnic differences are no longer significant
when statistical analysis is limited to patients given imat-
inib as first-line therapy. Our cohort as a whole failed to
achieve response rates seen in large-scale national studies
[17-23]. This constellation of findings has not been
reported in previous studies, and is likely reflective of a
unique patient population.
We found that women were more likely to present with
significant anemia and significant thrombocytosis. An
analysis of our MCV data found that values for women
were significantly (p = 0.02, 2-sample t-test) lower than
those for men, suggesting that the gender differences
observed are likely due to iron deficiency anemia, with
reactive thrombocytosis. At the same time, however, there
were no significant gender-based differences in Hasford
and Sokal risk stratification, or in treatment response. To
our knowledge, this combination of findings has not been
reported in previous studies.
Surprisingly, we also found that Hispanic CML patients
had lower risk stratification scores and correspondingly
greater likelihood of achieving 3-month CHR compared
to non-Hispanic patients as a whole when all patients are
analysed regardless of treatment type; these ethnic differ-
ences in treatment response are no longer significant
when analysis is limited to patients treated with imatinib
as first-lined therapy. These are novel findings that have
not been reported in previous studies, and may reflect a
trend of our non-Hispanic minority patients presenting
and performing more poorly than national norms.
Although true biological differences may play a role, we
believe that such differences may be attributable to the
unique ethnic and socio-economic profile of our patient
population at LAC+USC Medical Center, underscoring the
need for further study into the significance of these fac-
tors.
Methods
Collection and Analysis of Pre-treatment Data
We began by establishing a database of all patients pre-
senting with CML at LAC+USC Medical Center between
the years 1991–2008. We identified and obtained ade-
quate medical records for 87 CML patients. Data collected
included gender, ethnicity, city and zip code of residence,
date of birth, date of diagnosis, treatment, course of treat-
ment, and any noted side effects, as well as complete
blood count data at presentation (pre-treatment), com-
prised of hemoglobin (Hgb), hematocrit, mean corpuscu-
lar volume (MCV), mean corpuscular hemoglobin, mean
corpuscular hemoglobin concentration, platelet count,
white blood cell count (WBC), and a WBC differential.
Hasford and Sokal scores were calculated for all patients
as available data allowed. As spleen size was not reliably
or routinely recorded in our medical records, the mean
spleen size reported in the original Hasford study [26] was
used as a proxy in calculating the Hasford score of all
patients.
This data was then analysed in an overall context, as well
as by gender and ethnicity based stratifications, to yieldJournal of Hematology & Oncology 2009, 2:30 http://www.jhoonline.org/content/2/1/30
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our pre-treatment findings for this study. Patients who
were previously diagnosed with CML at an outside institu-
tion and undergoing treatment at time of presentation to
LAC+USC Medical Center were excluded from pre-treat-
ment prognostic analysis. The associations between
patient baseline demographic and clinical characteristics,
and gender and ethnicity were examined using contin-
gency tables and Fisher's exact tests. The MCV values were
compared using a 2-sample t test.
Collection and Analysis of Treatment Response Data
Treatment response was determined by assessing com-
plete hematologic response (CHR) after three months of
treatment. CHR was defined as a complete blood count
(CBC) with a white blood cell count below 10 × 109/L and
a differential of 0% immature granulocytes, a platelet
count below 450 × 109/L and less than 5% basophils with
a non-palpable spleen [23]. A chart review was performed
for each of the 87 CML patients in the database and three
month complete blood counts (CBC) were collected to
assess CHR status, although complete CBC data were
available for only 47 of the 87 patients. Spleen palpability
for individual patients could not be assessed due to limi-
tations discussed previously and was not included as a
variable in the final analysis. Data was collected from
both LAC-USC's computer-based charting system as well
as hand-written charts that were recorded before the com-
puter system was in place.
A contingency table and Fisher's exact were used to evalu-
ate the associations of prognostic factors, sex, and ethnic-
ity with CHR.
The 5% level of significance was used and p-values were 2-
sided. All analyses were performed using the SAS statisti-
cal package version 9.1 (SAS Institute Inc. Cary, North
Carolina, USA).
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